PATENT CLAIM ANALYSIS

Application Number: 16033008
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["546", "111000"]

Abstract:
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

Claim (Index 12):
The method according to  claim 10  wherein said diabetes is type I diabetes.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 95.0
- Lexical Diversity: 1.53846
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15556055', '13652187', '15667737', '15747697', '14888390']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7158311180748805
- 35 USC 102 Novelty (BERT): 0.5788982248051074
- Combined Prediction Score: 0.7021378287479033
- Mean Citation Score: 281.99261
- Max Citation Score: 582.18835
- Similarity Product: 339.3500519075215

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test